Recent studies have shown that small-molecule inhibitors targeting STT3A can effectively inhibit tumor cell N-glycosylation and enhance NK cell-mediated antitumor activity [40, 41], thus providing direct translational support for our findings. The gene discussed is STT3A; the disease is neoplasm.